Phase 3 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have tested negative for HIV (both HIV-1 and HIV-2)
- People who have been sexually active, specifically having had vaginal intercourse with a cisgender male partner at least twice in the last 3 months
- People who were assigned female sex at birth and identify as cisgender
- People who weigh 35 kg (approximately 77 pounds) or more
Who may not be able to join:
- People who have a known allergy or medical reason to avoid any ingredient in the study treatment
- People who have a current or long-term hepatitis B infection
- People who have been diagnosed with cancer in the last 5 years (certain treated skin cancers or early-stage cervical cancer may be exceptions — confirm with trial site)
- People who have previously taken cabotegravir, lenacapavir, or any other long-acting HIV prevention medication
- People who are currently taking, or who may need to take, certain medications that are not permitted during the study period, starting from 30 days before the study begins (confirm with trial site for the specific list)
- People who have ever received an HIV vaccine (for example, through a past research study), or who have received certain antibody treatments related to HIV within the 12 months before the study starts
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) Infection; Number of Participants who Experience At Least One Adverse Event (AE); Number of Participants who Discontinue Study Intervention Due to an AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.